Laboratoires Pierre Fabre plans to invest 60 million euros annually across Asia-Pacific to double regional revenue by 2032, prioritizing Asian markets over the United States.
The French maker of Eau Thermale Avene and Klorane closed 2025 with 3.2 billion euros in worldwide sales, with the regional expansion designed to lift global revenue past 5 billion euros by 2032.
Asia-Pacific excluding China brought in 170 million euros in 2025, while the Chinese dermo-cosmetics business delivered about 180 million euros. Chief executive Eric Ducournau plans to raise ex-China regional revenue past 300 million euros by 2032 and roughly double sales inside China, deploying an annual investment run-rate equal to 20 per cent of regional revenue.
Group revenue currently splits 55 per cent to dermo-cosmetics and 45 per cent to pharmaceuticals. Brands such as Eau Thermale Avene, Ducray and A-Derma anchor the consumer skincare portfolio, while oncology, rare diseases and medical dermatology make up the prescription pipeline.
Ducournau intends to equalize both divisions at a 50-50 share globally by 2032. That balancing hinges on Asian distribution, where pharmaceuticals currently represent 35 per cent of regional net sales.
External licensing and biotechnology partnerships feed the drug pipeline. Oncology has already expanded from 19 per cent of pharmaceutical revenue in 2018 to 41 per cent in 2025, targeting colorectal, lung and melanoma cancers.
Supply snarls during the pandemic prompted the group to re-evaluate factory footprints. Pierre Fabre will now place dedicated manufacturing capacity inside the region for both consumer formulas and pharmaceuticals rather than shipping finished units entirely out of Europe.
Source link
